ESPR Stock Analysis: Esperion Therapeutics | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 819m USD | 12M Return: 169.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 32.6M
Qual. Beats: 0
Rev. Trend: 88.1%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a US-based biopharmaceutical company focused on developing and commercializing oral, once-daily, non-statin medicines for adults with elevated LDL-C cholesterol, including patients with primary hyperlipidemia and heterozygous familial hypercholesterolemia. Its marketed product line includes NEXLETOL (bempedoic acid), NEXLIZET (bempedoic acid and ezetimibe), NILEMDO, and NUSTENDI, which work by inhibiting cholesterol biosynthesis and up-regulating LDL receptors. The company holds license and collaboration agreements with Daiichi Sankyo (both in Asia and Europe) and Otsuka Pharmaceutical to support its commercialization efforts. Headquartered in Ann Arbor, Michigan, Esperion was originally incorporated in 2008 under the name HDL Therapeutics before rebranding later that same year, and operates as a small-cap business within the health care and biotechnology sector.
- NEXLETOL and NEXLIZET prescription growth drives U.S. revenue
- Daiichi Sankyo partnership delivers European milestone and royalty payments
- Cash burn rate and potential dilutive financing remain key overhang
| Net Income: -7.42m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.04 > 0.02 and ΔFCF/TA 27.04 > 1.0 |
| NWC/Revenue: 38.04% < 20% (prev 18.42%; Δ 19.62% < -1%) |
| CFO/TA -0.04 > 3% & CFO -18.2m > Net Income -7.42m |
| Net Debt (390.2m) to EBITDA (39.9m): 9.78 < 3 |
| Current Ratio: 1.53 > 1.5 & < 3 |
| Outstanding Shares: last quarter (251.4m) vs 12m ago 28.16% < -2% |
| Gross Margin: 65.00% > 18% (prev 65.30%; Δ -0.30% > 0.5%) |
| Asset Turnover: 106.3% > 50% (prev 80.11%; Δ 26.24% > 0%) |
| Interest Coverage Ratio: 0.47 > 6 (EBIT TTM 39.8m / Interest Expense TTM 85.0m) |
| A: 0.34 (Total Current Assets 459.5m - Total Current Liabilities 300.4m) / Total Assets 462.5m |
| B: -3.56 (Retained Earnings -1.65b / Total Assets 462.5m) |
| C: 0.10 (EBIT TTM 39.8m / Avg Total Assets 393.3m) |
| D: -0.40 (Book Value of Equity -307.9m / Total Liabilities 770.5m) |
| Altman-Z'' = -9.11 = D |
| DSRI: 1.01 (Receivables 132.4m/81.3m, Revenue 418.2m/259.6m) |
| GMI: 1.00 (GM 65.30% / 65.00%) |
| AQI: 0.70 (AQ_t 0.00 / AQ_t-1 0.00) |
| SGI: 1.61 (Revenue 418.2m / 259.6m) |
| TATA: 0.02 (NI -7.42m - CFO -18.2m) / TA 462.5m) |
| Beneish M = -2.75 (Cap -4..+1) = A |
As of July 14, 2026, the stock is trading at USD 3.18 with a total of 59,090,500 shares traded. Over the past week, the price has changed by +0.63%, over one month by +0.95%, over three months by +43.24% and over the past year by +169.49%.
Current recommended Stop Loss: 3.10 (which is 2.5% or 2.7 ATR below the current price).
Esperion Therapeutics has received a consensus analysts rating of 3.71. Therefore, it is recommended to hold ESPR.
- StrongBuy: 2
- Buy: 2
- Hold: 2
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 3.2 | 0.3% |
P/E Forward = 4.6382
P/S = 1.9593
P/B = 98.4236
P/EG = -4.78
Revenue TTM = 418.2m USD
EBIT TTM = 39.8m USD
EBITDA TTM = 39.9m USD
Long Term Debt = 250.1m USD (from longTermDebt, last quarter)
Short Term Debt = 82.4m USD (from shortTermDebt, last quarter)
Debt = 546.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 2.56m
Net Debt = 390.2m USD (calculated: Debt 546.4m - CCE 156.2m)
Enterprise Value = 1.21b USD (819.5m + Debt 546.4m - CCE 156.2m)
Interest Coverage Ratio = 0.47 (Ebit TTM 39.8m / Interest Expense TTM 85.0m)
EV/FCF = -66.51x (Enterprise Value 1.21b / FCF TTM -18.2m)
FCF Yield = -1.50% (FCF TTM -18.2m / Enterprise Value 1.21b)
FCF Margin = -4.35% (FCF TTM -18.2m / Revenue TTM 418.2m)
Net Margin = -1.77% (Net Income TTM -7.42m / Revenue TTM 418.2m)
Gross Margin = 65.00% ((Revenue TTM 418.2m - Cost of Revenue TTM 146.4m) / Revenue TTM)
Gross Margin QoQ = 56.84% (prev 83.46%)
Tobins Q-Ratio = 2.62 (Enterprise Value 1.21b / Total Assets 462.5m)
Interest Expense / Debt = 15.55% (Interest Expense 85.0m / Debt 546.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 31.4m (EBIT 39.8m * (1 - 21.00%))
Current Ratio = 1.53 (Total Current Assets 459.5m / Total Current Liabilities 300.4m)
Debt / Equity = -1.77 (negative equity) (Debt 546.4m / totalStockholderEquity, last quarter -307.9m)
Debt / EBITDA = 9.78 (Net Debt 390.2m / EBITDA 39.9m)
Debt / FCF = -21.46 (negative FCF - burning cash) (Net Debt 390.2m / FCF TTM -18.2m)
Total Stockholder Equity = -373.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.89% (Net Income -7.42m / Total Assets 462.5m)
RoE = 1.99% (negative equity) (Net Income TTM -7.42m / Total Stockholder Equity -373.7m)
RoCE = -32.19% (negative capital employed) (EBIT 39.8m / Capital Employed (Equity -373.7m + L.T.Debt 250.1m))
RoIC = 14.05% (NOPAT 31.4m / Invested Capital 223.7m)
WACC = 13.21% (E(819.5m)/V(1.37b) * Re(13.82%) + D(546.4m)/V(1.37b) * Rd(15.55%) * (1-Tc(0.21)))
Discount Rate = 13.82% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 81.29 | Cagr: 43.00%
[DCF] Fair Price = unknown (Cash Flow -18.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.42 | # QB: 0
Revenue Correlation: 88.12 | Revenue CAGR: 67.43% | SUE: -0.25 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.07 | Chg30d=N/A | Revisions=+25% | Analysts=1
EPS next Quarter (2026-09-30): EPS=-0.04 | Chg30d=N/A | Revisions=+25% | Analysts=1
EPS current Year (2026-12-31): EPS=-0.21 | Chg30d=N/A | Revisions=+25% | GrowthEPS=-90.9% | GrowthRev=-16.3%
EPS next Year (2027-12-31): EPS=0.29 | Chg30d=-0.44% | Revisions=+0% | GrowthEPS=+239.0% | GrowthRev=+35.3%
[Analyst] Revisions Ratio: +50% (up=3, down=0)